Program
teclistamab
Also written as “Teclistamab”, “Teclistamab (IV)” and “Teclistamab(SC)”.
Its studies are mostly in Multiple Myeloma · Hematologic Neoplasms, led by Johnson & Johnson.
Furthest: phase 4, since Jun 12, 202511 company-led studies, 10 open or runningNext primary completion: Feb 12, 2027 (phase 4)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 1110 open or running | phase 4since Jun 12, 2025 | Apr 28, 2017 | Feb 12, 2027phase 4 · NCT07030517 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 28, 2017First study: phase 1 study in Hematologic NeoplasmsFirst studyNCT03145181 · 302 enrolled · United States, France, Netherlands and more
- Sep 17, 2020Phase 2 study in Hematologic NeoplasmsNCT04557098 · 194 enrolled · United States, Belgium, Canada and more
- Oct 12, 2020Phase 2 study in Multiple MyelomaNCT04586426 · 228 enrolled · United States, Australia, Canada and more
- Jan 5, 2021Phase 2 study in Hematologic NeoplasmsNCT04696809 · 40 enrolled · Japan
- Oct 8, 2021Phase 3 study in Multiple MyelomaNCT05083169 · 587 enrolled · United States, Argentina, Belgium and more
- Mar 31, 2022Phase 1 study in Relapsed/ Refractory Multiple MyelomaNCT05338775 · 74 enrolled · United States, France, Germany and more
- Sep 21, 2022Phase 3 study in Multiple MyelomaNCT05552222 · 1,590 planned · United States, Australia, Austria and more
- Oct 5, 2022Phase 3 study in Multiple MyelomaNCT05572515 · 614 enrolled · United States, Australia, Austria and more
- Jan 5, 2024Phase 3 study in Multiple MyelomaNCT06208150 · 838 enrolled · United States, Argentina, Australia and more
- May 17, 2024Phase 1 study in Multiple MyelomaNCT06425991 · 108 enrolled · United States, Australia, Canada and more
- Jun 12, 2025Phase 4 study in Multiple MyelomaNCT07030517 · 75 enrolled · India
- Nov 3, 2026Primary completion moved from 2026-11-03 to 2027-02-12Date moved laterphase 4 · +3 months · NCT07030517
Ahead
- Feb 12, 2027Primary completion: phase 4 study in Multiple MyelomaNCT07030517
- Apr 30, 2031Primary completion: phase 3 study in Multiple MyelomaNCT05552222
TargetBeta
“A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, ”NCIt, by rule
“T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elranatamabrule | Pfizer | phase 4 | 15 |
| linvoseltamabrule | Regeneron Pharmaceuticals | phase 4 | 13 |
| etentamig | AbbVie | phase 3 | 11 |
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| cizutamigrule | UCB | phase 2 | 5 |
| vonsetamigrule | Regeneron Pharmaceuticals | phase 2 | 3 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010rule | kelonia-therapeutics-inc | phase 1 | 1 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07030517Multiple Myeloma · India | 4 | Active, not recruiting | Feb 12, 2027 | 75 |
| NCT06425991Multiple Myeloma · United States, Australia, Canada and more | 1 | Active, not recruiting | Apr 21, 2025 | 108 |
| NCT06208150Multiple Myeloma · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 1, 2026 | 838 |
| NCT05572515Multiple Myeloma · United States, Australia, Austria and more | 3 | Active, not recruiting | Oct 13, 2025 | 614 |
| NCT05552222Multiple Myeloma · United States, Australia, Austria and more | 3 | Recruiting | Apr 30, 2031 | 1,590 |
| NCT05338775Relapsed/ Refractory Multiple Myeloma · United States, France, Germany and more | 1 | Active, not recruiting | May 22, 2025 | 74 |
| NCT05083169Multiple Myeloma · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Aug 1, 2025 | 587 |
| NCT04696809Hematologic Neoplasms · Japan | 2 | Completed | Apr 13, 2026 | 40 |
| NCT04586426Multiple Myeloma · United States, Australia, Canada and more | 2 | Active, not recruiting | Mar 18, 2025 | 228 |
| NCT04557098Hematologic Neoplasms · United States, Belgium, Canada and more | 2 | Active, not recruiting | Nov 9, 2021 | 194 |
| NCT03145181Hematologic Neoplasms · United States, France, Netherlands and more | 1 | Active, not recruiting | Sep 25, 2025 | 302 |
How it is read
Names in the registry
- “Teclistamab”, 10 entries
- “Teclistamab (IV)”, 1 entry
- “Teclistamab(SC)”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 8 studies
- Hematologic Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.